Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AssigneeNovo Nordisk Pharmaceuticals, Inc.
InventorsBrit Binow Sorensen, Lars Christian Petersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions increased or decreased cell apoptosis is required.
Claims22
A method for reducing or inhibiting apoptosis of a cell population, said method comprising contacting said cell population with an effective amount for reducing apoptosis of a tissue factor agonist.
A method of treating a pathological condition characterized by an elevated level of apoptosis, said method comprising administering to an individual in need of such treatment an effective amount for treating said condition of a pharmaceutical composition comprising a tissue factor agonist.
A method for inducing or enhancing apoptosis of a cell population, comprising the step of contacting said cell population with an effective amount for inducing or enhancing apoptosis of a tissue factor antagonist.
A method of treating a condition characterized by a reduced level of apoptosis, said method comprising administering to an individual in need of such treatment an effective amount for treating said condition of a pharmaceutical composition comprising a tissue factor antagonist.
Use of a tissue factor agonist for the manufacture of a medicament for treatment of disease or condition associated with undesired apoptosis of a cell population.
Use of a tissue factor antagonist for the manufacture of a medicament for treatment of disease or condition, where induction or enhancement of apoptosis of a cell population is desired.
A method for regulating apoptosis in a cell population, said method comprising contacting said cells with one or more of a tissue factor agonist and a tissue factor antagonist.
Dependencies are inferred from the claim text.